Literature DB >> 33987515

What's new in chronic pain pathophysiology.

Ivan Cohen1, Mark J Lema1.   

Abstract

The understanding of pain pathophysiology is continuously evolving. Identifying underlying cellular and subcellular pathways helps create opportunities for targeted therapies that may prove to be effective interventions. This article is an update on four areas of developing knowledge as it pertains to clinical management of patients with pain: nerve growth factor antagonists, microglial modulation, AMP-activated protein kinase activators, and genetic pain factors. Each of these areas represents novel targets for targeted therapies to prevent, treat, and modify the disease course of acute, chronic, and neuropathic pain. Currently most pain management techniques do not target these pathways directly, but there is promising evidence to suggest that the field is advancing toward available therapies in the near future.
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.

Entities:  

Keywords:  AMPK; genetics; microglia; nerve growth factor; pain pathophysiology

Year:  2020        PMID: 33987515      PMCID: PMC7942794          DOI: 10.1080/24740527.2020.1752641

Source DB:  PubMed          Journal:  Can J Pain        ISSN: 2474-0527


  24 in total

1.  Post-injury administration of minocycline: an effective treatment for nerve-injury induced neuropathic pain.

Authors:  Xiao-Peng Mei; Hao Xu; Cheng Xie; Jun Ren; Yang Zhou; Hui Zhang; Li-Xian Xu
Journal:  Neurosci Res       Date:  2011-04-14       Impact factor: 3.304

Review 2.  AMPK: An emerging target for modification of injury-induced pain plasticity.

Authors:  Theodore J Price; Gregory Dussor
Journal:  Neurosci Lett       Date:  2013-07-03       Impact factor: 3.046

3.  Potential association of DRD2 and DAT1 genetic variation with heroin dependence.

Authors:  Qiao-Fang Hou; Sheng-Bin Li
Journal:  Neurosci Lett       Date:  2009-08-05       Impact factor: 3.046

4.  Spinal cord stimulation reduces mechanical hyperalgesia and glial cell activation in animals with neuropathic pain.

Authors:  Karina L Sato; Lisa M Johanek; Luciana S Sanada; Kathleen A Sluka
Journal:  Anesth Analg       Date:  2014-02       Impact factor: 5.108

5.  The role of hydromorphone and OPRM1 in postoperative pain relief with hydrocodone.

Authors:  Mark V Boswell; M Elaine Stauble; Gary E Loyd; Loralie Langman; Bronwyn Ramey-Hartung; Richard N Baumgartner; William W Tucker; Saeed A Jortani
Journal:  Pain Physician       Date:  2013 May-Jun       Impact factor: 4.965

Review 6.  Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.

Authors:  L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1995-09       Impact factor: 6.447

7.  Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities.

Authors:  M T Tsuang; M J Lyons; J M Meyer; T Doyle; S A Eisen; J Goldberg; W True; N Lin; R Toomey; L Eaves
Journal:  Arch Gen Psychiatry       Date:  1998-11

Review 8.  Microglia and spinal cord synaptic plasticity in persistent pain.

Authors:  Sarah Taves; Temugin Berta; Gang Chen; Ru-Rong Ji
Journal:  Neural Plast       Date:  2013-08-18       Impact factor: 3.599

Review 9.  Structure and Physiological Regulation of AMPK.

Authors:  Yan Yan; X Edward Zhou; H Eric Xu; Karsten Melcher
Journal:  Int J Mol Sci       Date:  2018-11-09       Impact factor: 5.923

Review 10.  Ion Transporters, Channelopathies, and Glucose Disorders.

Authors:  Huseyin Demirbilek; Sonya Galcheva; Dogus Vuralli; Sara Al-Khawaga; Khalid Hussain
Journal:  Int J Mol Sci       Date:  2019-05-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.